REG - Physiomics PLC - Director Dealing

PhysiomicsAnnouncement

25/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230725:nRSY0202Ha&default-theme=true

RNS Number : 0202H  Physiomics PLC  25 July 2023

25 July 2023

 

Physiomics plc

("PYC" or the "Company")

 

Director Dealing

 

The Company announces that Dr Jim Millen, Chief Executive Officer of
Physiomics, has transferred, for no consideration, 500,000 ordinary shares of
0.4p each in the Company held in certificated form ("Ordinary Shares") to his
nominee account with Interactive Investor Services Limited. The Ordinary
Shares remain beneficially owned by Dr Millen.

 

Accordingly, Dr Millen's total holding in the Company will remain unchanged
at 1,884,393 Ordinary Shares, representing approximately 1.39 per cent. of the
Company's issued share capital.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen,
CEO
+44 (0)1865 784 980

 

Hybridan LLP (Broker)
 
+44 (0) 203 764 2341

Claire Louise Noyce

 

Strand Hanson Ltd (NOMAD)
 
  +44 (0)20 7409 3494

James Dance

James Bellman

 

 

 

 

The Company's LEI is 213800A71DSZ6ABMTQ91

 

 

PDMR Notification Forms

 

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         James Millen
 2.  Reason for the Notification
 a)  Position/status                                              Executive Chairman and CEO
 b)  Initial notification/amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Physiomics plc
 b)  LEI                                                          213800A71DSZ6ABMTQ91
 4.  Details of the transaction(s):section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv)each place
     where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Physiomics plc Ordinary Shares
     Identification code                                          ISIN:  GB00BDR6W943
 b)  Nature of the Transaction                                    Transfer of securities held in paper share certificates to nominee account
                                                                  Interactive Investor Services Nominees Limited.
 c)  Price(s) and volume(s)                                       Dr Jim Millen

Price(s)  Volume(s)
                                                                  N/A       500,000
 d)  Aggregated information

     -       Aggregated volume                                    500,000

                                                                  N/A

     -       Price

 e)  Date of the transaction                                      22 July 2023
 f)  Place of the transaction                                     Off market transaction

d)

Aggregated information

-       Aggregated volume

 

-       Price

 

 

500,000

N/A

e)

Date of the transaction

22 July 2023

f)

Place of the transaction

Off market transaction

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 100 projects, involving over 50 targets and 75 drugs, and
has worked with clients such as Merck KGaA, Astellas, Merck & Co and
Bicycle Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHRIMRTMTMTBIJ